Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079886 | 0.82 | RAB9A (0.51) | NAMPTKMT2A | |
| SCHEMBL6079669 | 0.82 | HDAC3 (0.43) | NAMPTKMT2A | |
| SCHEMBL6079540 | 0.81 | HTR2C (0.35) | SYKKMT2AGPR119RXRAGRIN1 | |
| SCHEMBL6079210 | 0.81 | SIRT2 (0.51) | SYKNAMPTCYP17A1 | |
| SCHEMBL6078849 | 0.79 | BRAF (0.48) | KMT2A | |
| SCHEMBL6078955 | 0.79 | CA12 (0.45) | SYKNAMPTCYP17A1RORCMAPKAPK2 | |
| SCHEMBL6080568 | 0.77 | KMT2A (0.48) | KMT2A | |
| SCHEMBL22941793 | 0.75 | CA12 (0.44) | SYKCYP17A1RORCCA12CA1 | |
| SCHEMBL13244160 | 0.75 | CA12 (0.44) | SYKNAMPTCYP17A1RORCMAPKAPK2 | |
| SCHEMBL6079909 | 0.75 | MAPK14 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | SYK 1316/4885NAMPT 1734/4885CYP17A1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.